These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1755767)

  • 41. Ovarian ablation as a treatment for breast cancer.
    Sainsbury R
    Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Italian study on the chemoprevention of breast cancer with tamoxifen].
    Veronesi U; Costa A; Sacchini V; Luini A; Bonanni B; Veronesi P; Rotmensz N; Boyle P
    Contracept Fertil Sex; 1995 Apr; 23(4):258-60. PubMed ID: 7757133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of HRT and the subsequent risk of cancer.
    Beral V; Banks E; Reeves G; Appleby P
    J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
    Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
    [No Abstract]   [Full Text] [Related]  

  • 48. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
    Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
    Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Can breast cancer be prevented?].
    Vatten LJ
    Tidsskr Nor Laegeforen; 1991 May; 111(14):1745-8. PubMed ID: 2063386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoprevention of breast cancer: implications for postmenopausal women.
    Fabian CJ; Kimler BF
    Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The endocrine prevention of breast cancer.
    Howell A
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population attributable risk of modifiable risk factors associated with invasive breast cancer in women aged 45-69 years in Queensland, Australia.
    Wilson LF; Page AN; Dunn NA; Pandeya N; Protani MM; Taylor RJ
    Maturitas; 2013 Dec; 76(4):370-6. PubMed ID: 24113278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer.
    Shulman A; Cohen I; Altaras MM; Maymon R; Ben-Nun I; Tepper R; Beyth Y
    Hum Reprod; 1994 Aug; 9(8):1427-9. PubMed ID: 7989499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
    Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
    JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.